Shanghai Benyao Technology

Shanghai Benyao Technology Co., Ltd., operating as Bioyond, is a life sciences company established in March 2021 with headquarters in Shanghai's Zhangjiang Science City. The firm was founded by Tang Yang, who serves as CEO. His background includes extensive experience in the robotics industry, having held leadership roles at ABB Robotics, including President of the China R&D Center and President of the Consumer and Service Robotics Business Unit in China. This experience in robotics and automation is central to Bioyond's operational focus.

The company engineers intelligent automation solutions for the life sciences sector by integrating robotics, artificial intelligence, and high-precision visual recognition technologies. Its business-to-business model serves a client base that includes pharmaceutical companies, clinical diagnostics labs, and scientific research institutions. Bioyond has developed a portfolio of modular automation products and comprehensive solutions designed to address repetitive and labor-intensive tasks in laboratory settings, such as liquid handling and sample preparation. The core of its technology rests on three platforms: robotics, automation, and a data and cloud system. This infrastructure allows for the creation of flexible and rapidly deployable automation systems built from a suite of self-developed robots, instrument modules, and intelligent software. An advanced AI and computing engine enables the processing of large datasets to support scientific analysis and decision-making for R&D and production personnel.

Since its inception, Bioyond has secured significant financial backing. Sequoia China Seed Fund was involved from the incubation stage and provided angel financing in early 2021. The company has since completed multiple funding rounds, including a Pre-A round in the same year led by Qiming Venture Capital, and subsequent Series A and A+ rounds co-led by Boyuan Capital and Lilly Asia Fund (LAV), with participation from CICC Qide Fund. By early 2023, the company had raised approximately 300 million RMB. A Series A3 financing round was announced in October 2024, led by Panlin Capital, with continued investment from existing backers like Qiming Venture Capital and Boyuan Capital. These funds are allocated towards product and technology development, platform construction, and market expansion to enhance automation solutions for its target markets.

Keywords: life science automation, laboratory robotics, intelligent automation, drug discovery automation, clinical diagnostics solutions, cell therapy automation, synthetic biology tools, scientific research automation, automated lab equipment, liquid handling robotics, AI in life sciences, Shanghai Benyao Technology, Bioyond, Tang Yang, lab automation systems, pharmaceutical automation, automated sample preparation, robotics in diagnostics, life science data analysis, high-throughput screening automation